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establishing diagnostic mechanisms that enable rapid testing of these 
hypotheses in the clinic. This dual approach may provide a framework 
for a new clinical science that is driven by the knowledge of the mo-
lecular biology of individual tumors rather than by empirical determi-
nants of drug response. 
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sensitivity of EGFR wild type NSCLC and HNSCC cell lines to 
gefitinib and cetuximab 
Yonesaka, Kimio1,2,3,4 Zejnullahu, Kreshnik1,2 Homes, Alison J.1,2 
Johnson, Bruce E.1,2,3,4 Janne, Pasi A.1,2,3,4 
1 Lowe Center for Thoracic Oncology, Boston, MA, USA 2 Department 
of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA 
3 Departments of Medicine, Brigham and Women’s Hospital, Boston, 
MA, USA 4 Havard Medical School, Boston, MA, USA 
Background: Epidermal growth factor receptor (EGFR) is a thera-
peutic target in non-small cell lung cancer (NSCLC) and head and 
neck squamous cell carcinoma (HNSCC). Patients with NSCLC with 
activating mutations in EGFR often have signiﬁcant tumor regressions 
with geﬁtinib treatment. In addition, approximately 30% of patients 
treated with geﬁtinib develop stable disease implicating additional 
mechanisms of geﬁtinib sensitivity. The majority of such patients do 
not harbor EGFR mutations and EGFR mutations in HNSCC are rare. 
As EGFR can be activated by one of its ligands (amphiregulin, EGF, 
TGF-alpha), we examined the relationship of EGFR ligands to the ef-
ﬁcacy of geﬁtinib and cetuximab using in vitro growth assays of EGFR 
wild type NSCLC and HNSCC cell lines. 
Methods: Amphiregulin, EGF and TGF-alpha in cell culture media 
was analyzed with ELISA assays in 18 cell lines, 14 NSCLC and 4 
HNSCC cell lines. This included four NSCLC with EGFR mutation. 
The remaining 14 cell lines were wild type for EGFR. All had wild type 
KRAS except for H358. The in vitro sensitivity was analyzed using 
MTS assay. EGFR, HER3, Akt, ERK1/2, Cyclin D1 and phosphoryla-
tion of these proteins were analyzed with Western blotting. Cell cycle 
was analyzed by ﬂow cytometry.
Result: TGF-alpha (range, 0 to 4.8pg/ml) was only detected in Calu3 
(116.6pg/ml) and H1666 (4.8pg/ml) cells. EGF (range, 0 to 2.2pg/ml) 
was detected at negligible level and did not vary signiﬁcantly. The pres-
ence of amphiregulin varied signiﬁcantly among the cell lines (range, 
4.6 to 1625.8pg/ml). All EGFR mutant cell lines had negligible levels 
of amphiregulin (<50.3pg/ml). Seven cell lines of the 14 cell lines 
with wild-type EGFR had > 250 pg/ml (range, 718.4 to 1625.8pg/ml) 
of amphiregulin detectable in media and all were sensitive to geﬁtinib 
with an IC50 of < 1 uM (range, 0.10 to 0.33). In addition, they were 
also sensitive to cetuximab (mean growth inhibition following10ug/ml 
cetuximab 56.8% (range, 33.1 to 87.1 %)) while those producing < 250 
pg/ml were resistant (mean growth inhibition following 10ug/ml cetux-
imab 0.95% (range -4.4 to 15.3%). Cell lines producing < 250 pg/ml 
of amphiregulin were also resistant to geﬁtinib in vitro (IC > 1 uM) In 
addition 6/7 sensitive cell lines expressed p-ERBB3 in contrast to 1/7 
resistant cell lines. The amphiregulin producing cell lines underwent 
G1/S arrest following either geﬁtinib or cetuximab treatment. Fur-
thermore, amphiregulin neutralizing antibodies inhibited growth of 3 
amphiregulin producing cell lines but not HN28, which did not produce 
amphiregulin. Amphiregulin producing sensitive cell lines exhibited 
dose dependent decrease in p-EGFR, p-ERBB3, p-Akt, p-ERK 1/2 and 
cyclin D1 following geﬁtinib. Cetuximab led to a dose dependent de-
crease in p-EGFR, p-ERK 1/2 and cyclin D1. Geﬁtinib and cetuximab 
had no effect on these proteins in cells without amphiregulin.
Conclusion: Our ﬁndings suggest that in EGFR wild type NSCLC and 
HNSCC cell lines the presence of an amphiregulin autocrine loop is a 
major determinant of in vitro sensitivity to geﬁtinib and cetuximab. In 
addition to EGFR mutations, amphiregulin expression may be suitable 
biomarker to select patients likely to beneﬁt from geﬁtinib treatment. 
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cancer: a Norwegian experience
Rolke, Heidi B. Gallefoss, Frode 
Dept. of Pulmonolgy, Sorlandet Hospital, Kristiansand S, Norway
Background: Few details are known about the smoking history of 
patients developing lung cancer, especially so for users of hand rolled 
cigarettes. Norway appears to be the last Western country still using 
a signiﬁcant amount of roll tobacco, amounting to one third of total 
tobacco sales.
Methods: A prospective, questionnaire-based study on all persons de-
veloping primary lung cancer in Southern Norway between June 14th, 
2002 and June 13th, 2005.
Results: 83% of patients in an unselected population with newly 
diagnosed lung cancer had smoked primarily hand rolled cigarettes. 
The hand rolled cigarette smokers had consumed signiﬁcantly less 
pack-years of tobacco (32,3, SD19), and smoked fewer cigarettes per 
day (14,9 SD7), than those using fabricated cigarettes (40,0, SD26, 
and 19,8, SD10, p=0,023 and p<0,0001, respectively). The use of pack 
tobacco is much more frequent in this study than expected from ofﬁcial 
sales statistics. Smoking debut was 17,9 years (SD5). Mean age for 
developing lung cancer was 68 (SD11) years.
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Conclusion: Patients smoking hand rolled cigarettes developing 
primary lung cancer have a smoking history of fewer cigarettes per day 
and less pack years tobacco consume than those smoking fabricated 
cigarettes, enhancing the opinion that hand rolled cigarettes are more 
carcinogenic. The use of hand rolled cigarettes among people develop-
ing lung cancer in Southern Norway is much higher than the average 
consume khown from ofﬁcial sales statistics.
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Objectives: In order to further characterize the difference of gender on 
the clinical, pathological status, survival and its predictive factors of 
patients on population-based lung cancer, and to determine time trends 
of gender differences, we analyzed the data which had been entered 
into Shanghai Cancer Registry System and executed by CDC. 
Methods: Data on demographics, stage at diagnosis, history and 
survival were obtained for all patients with primary bronchogenic 
carcinoma registered in Shanghai cancer registry system from 2002 to 
2004. The time trends of the male and female incidence in the urban 
population from 1972 to 2004 were assessed using APC (annual per-
cent change) analysis. Relative survival rates based on life-table analy-
sis methods were calculated to estimate the beneﬁt of cancer survival 
by compensating for the expected difference in baseline survival rates 
between male and female populations. Cox multi-variance analyses 
were used to evaluate prognostic factors; those factors were gender, 
age, residential area, pathological type, stage, and hospital grade. 
Results: 23196 new cases of lung cancer were diagnosed during 2002 
– 2004, the female crude incidence rate was 33.73/100000, and age-
adjusted rate was 30.90/100000. The male crude incidence rate and the 
age-adjusted rate were higher than those of female. The APC of male 
and female crude incidence continued to rise during the past 33 years 
(1.723% vs 2.036%, p <0.01). The male age-adjusted incidence rate 
in tendency to reduce was seen in the urban area (APC was -0.605%, 
p <0.01), but no change in female (APC was -0.136, p >0.05). There 
were more stage IV cases and adenocarcinoma in women than those 
of men (47.5% vs. 40.0%, 86.1% vs. 47.8%, respectively, p <0.05).
The overall 3-year survival rates and MST were signiﬁcantly higher 
in women than men (17.05% vs. 14.01% 0.83 year vs. 0.77 year, p < 
0.01). Stage-speciﬁc survival rates of women were also statistically 
higher than those of men for each stage (p < 0.05). The 3-year survival 
rates and MST were also signiﬁcantly higher in women adenocar-
cinoma than men (30.38%: 22.66%, 1.48 year: 0.98 year, p <0.01). 
Female gender was an independent positive prognostic factor (p < 0.01) 
by a multivariate Cox analysis, other positive prognostic factors were 
younger, urban area, squamous cancer, early stage, high-grade hospital. 
Conclusion: Shanghai is one of the high-incidence area of lung cancer 
in the world. The present study conﬁrms that women had statistically 
better outcomes than men in different stages of disease. The reasons 
behind these gender differences remain unclear. Exogenous or endog-
enous estrogens, gene, smoking, psychology, etc, may play roles to 
develop of the lung cancer in women.
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Background: Since 1997, lung cancer has become the leading cause 
of cancer deaths for both men and women in Taiwan. Gender-related 
differences in terms of histologic subtypes, stage at presentation, and 
survival rates have been reported but with conﬂicting ﬁndings. There 
is a growing global concern regarding cancer in women. With the 
introduction of new diagnostic and therapeutic modalities, this study 
was conducted to evaluate the trends of non-small cell lung cancer 
(NSCLC) between genders in recent years. 
Methods: A cohort of consecutive patients diagnosed with NSCLC at a 
180-bed referral cancer center in Taipei, who were clinically (including 
integrated positron emission tomography and computed tomography 
[PET/CT]) and pathologically staged by a surgeon and a pulmonologist 
experienced in video-assisted thoracoscopic surgery and trans-bron-
chial needle aspiration (TBNA) respectively, underwent homogenous 
treatment algorithms (i.e. new chemotherapeutic agents, target therapy, 
and 3D conformal radiotherapy) from January 2002 and followed-up 
until the end of 2006. Primary outcomes were the survival estimates 
derived by Kaplan-Meier analysis. 
Results: There were 738 patients (329 women and 409 men), who pre-
sented at a similar stage (p=0.95). The women were younger (mean age: 
58.4 vs. 62.2 year; p<0.001) and better overall age-adjusted and stage-
adjusted survival (p<0.001). Stage-speciﬁc survival favored women, 
with the differences becoming more signiﬁcant towards advanced stages 
(stage I disease, p=0.35; stage II, p=0.97; stage III, p=0.04; and stage 
IV, p<0.001). Among the 602 patients with unequivocal pathologic 
diagnosis, women were more likely to have adenocarcinoma (93.95%, 
p<0.001), which also comprised the majority (75.08%) in men. Patients 
with adenocarcinoma had better survival than those with squamous cell 
carcinoma (p=0.008). Pure bronchio-alveolar carcinoma (BAC) ac-
counted for 4.95% of adenocarcinoma and disproportionately occurred 
in women (72%). Survival was signiﬁcantly higher in patients with 
pure BAC histology than in those with adenocarcinoma other than BAC 
(p=0.02). In contrast with previous reports on recurrence patterns of 
BAC, an early and distinctly BAC hilar-mediastinal recurrence exclu-
sively in female patients was diagnosed by sequential serum carcino-
embryonic antigen follow-up and PET/CT-guided TBNA. 
Conclusions: There are gender-associated differences in the clinico-
pathologic characteristics and survival of NSCLC patients in the new 
era. The results can help guide pro-active government policies regard-
ing cancer and have the clinical importance for practicing clinician 
and/or researchers. Aggressive approaches to identify epidemiologic 
and biologic trends of lung cancer are needed at both the national and 
